# US 2026/0097015 A1 · Extended release formulations comprising substituted indazole propionic acid derivative compounds and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097015 A1
- Document ID: US20260097015A1
- Status: Published application
- Kind: A1
- Application number: 19/348,897
- Filed: 2025-10-03
- Published: 2026-04-09
- Earliest claimed: 2024-10-04
- Assignees: Pfizer Inc.
- Applicants: Pfizer Inc.
- Inventors: Alfred Berchielli; Brett John Kopina
- Web page: https://patentgrep.com/patent/US20260097015A1

## CPC

- A61K 31/416: condensed with carbocyclic ring systems, e.g. indazole
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/5015: {Organic compounds, e.g. fats, sugars}
- A61K 9/5026: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/425: Thiazoles
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to extended-release formulations comprising substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof that can activate adenosine 5′-monophosphate-activated protein kinase (AMPK). The invention further relates to methods of treating a condition comprising administering an extended-release formulation comprising AMPK-activating substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof.

## Claims

### Claim 1

A composition comprising:
a) a compound of Formula (I):
a pharmaceutically acceptable salt, a tautomer, or a pharmaceutically acceptable salt of the tautomer thereof, wherein:
A1 is CR8, or N;
A2 is CH2, CHD, CD2, S, O, or NH;
A3 is CH, CD, or N;
R1 is H, D, C1-8alkyl, C3-6cycloalkyl, or 4-6 membered heterocycloalkyl, each of which is optionally substituted;
R2, R3, R5, and R6 are each independently H, D, OH, or halogen;
R4 is monocyclic aryl, bicyclic aryl, monocyclic heteroaryl, or bicyclic heteroaryl, each of which is optionally substituted with R9, R10, R11, R12, or R13,
wherein R9, R10, R11, R12, and R13 are each independently H, D, halogen, CN, oxo, C1-8alkyl, C3-6cycloalkyl, examC0-6alkylene-ORx, C1-6haloalkylene-ORx, C0-6alkylene(C0-6haloalkyl)NRRy, C1-6alkylene(C1-6haloalkyl)NRRy, 4-6 membered heterocycloalkyl, C(O)ORx, C0-6alkylene-C(O)NRxRy, OC1-3alkylene-heterocycloalkyl, OC1-3alkylene-C(O)NRxRy, O(C1-6alkyl)SO2NRxNRy, NRxRy, NHSO2Rx, SRx, S—C1-6alkylene-C(O)NRxRy, S(O)RxRy, SO2Rx, SO2NRxRy, S(O)(NRx)Ry, S(O)(NRx)Ry, or SO2Rx; wherein each Rx and Ry is independently H, D, C1-6alkyl, C1-6haloalkyl, C1-6alkoxy, C3-6cycloalkyl, C1-6alkylene-amide, OC0-2alkylene-heterocycloalkyl, 4-6 membered heterocycloalkyl, C(O)C1-6alkyl, imino, or C1-6alkylsulfonyl; or Rx and Ry together with the atoms to which Rx and Ry are bound can form an optionally substituted ring;
R7 is C1-3alkyl, C3-6cycloalkyl, cyano, or halogen;
Rb1, Rb2, and Rb3 are each independently H or D;
R3 is H, D, or halogen; and
n is 0, 1, or 2;
b) a matrix component; and
c) a release modifier,
wherein the composition is an extended-release composition.

### Claim 2 (depends on 1)

The composition of claim 1, consisting essentially of:
a) the compound of Formula (I), a pharmaceutically acceptable salt, a tautomer, or a pharmaceutically acceptable salt of the tautomer thereof;
b) the matrix component; and
c) the release modifier.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the matrix component is selected from the group consisting of: stearyl alcohol, polyglyceryl-4-stearate, and polyglyceryl-6-palmate.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the composition comprises the matrix component in an amount of from about 25% to about 90% w/w.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the release modifier is selected from the group consisting of crospovidone, poloxamer 407, sodium starch glycolate Type A (SSG-A), polyglyceryl-4-stearate, polyglycerol-3-behenate.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the composition comprises the release modifier in an amount of from about 3% to about 30% w/w.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the composition comprises the compound of Formula (I), or a pharmaceutically acceptable salt, the tautomer, or the pharmaceutically acceptable salt of the tautomer thereof, in an amount of from about 5% to about 50% w/w.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the composition comprises the compound of Formula (I), or the pharmaceutically acceptable salt, the tautomer, or the pharmaceutically acceptable salt of the tautomer thereof, wherein A1 is CH or CF; A2 is CH2 or S; and A3 is N.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the composition comprises the compound of Formula (I), or the pharmaceutically acceptable salt, the tautomer, or the pharmaceutically acceptable salt of the tautomer thereof, wherein R1, R2, R3, R5, and R6 are each independently H; and R7 is Cl.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the composition comprises the compound of Formula (I), or the pharmaceutically acceptable salt, the tautomer, or the pharmaceutically acceptable salt of the tautomer thereof, wherein R4 is phenyl, wherein R9, R10, R11, R12, and R13 are each independently H, D, Cl, F, CN, C1-3alkyl, C1-6alkylene-OH, C1-6alkylene-OC1-6alkyl, OH, OC1-6alkyl, OC1-6haloalkyl, O(C1-3alkylene)heterocycloalkyl, O(C1-3alkylene)-C(O)NRxRy, C1-3alkylene-NRxRy, C(O)OH, C(O)OC1-3alkyl, C0-2alkylene-C(O)NRxRy, SO2NRxRy, S(O)(NRx)Ry, NRxRy, SRx, or SO2Rx.

### Claim 11 (depends on 1)

The composition of claim 1, wherein the compound of Formula (I) is selected from the group consisting of:
3-(6-Chloro-5-(2′-hydroxy-[1,1′-biphenyl]-4-yl)-1H-indazol-3-yl)propanoic acid;
3-(6-chloro-5-(2′-hydroxy-6′-methyl-[1,1′-biphenyl]-4-yl)-1H-indazol-3-yl)propanoic acid;
3-(6-chloro-5-(2′-hydroxy-3′-methoxy-[1,1′-biphenyl]-4-yl)-1H-indazol-3-yl)propanoic acid;
3-(6-chloro-5-(2′-hydroxy-3′-methoxy-6′-methyl-[1,1′-biphenyl]-4-yl)-1H-indazol-3-yl)propanoic acid;
3-(6-chloro-5-(4-(7-hydroxy-2,3-dihydrobenzofuran-6-yl)phenyl)-1H-indazol-3-yl)propanoic acid;
3-(6-chloro-5-(2′-hydroxy-4′-(methoxymethyl)-[1,1-biphenyl]-4-yl)-1H-indazol-3-yl)propanoic acid;
3-(6-chloro-5-(2′-hydroxy-4′,6′-dimethyl-[1,1-biphenyl]-4-yl)-1H-indazol-3-yl)propanoic acid;
3-(6-chloro-5-(3′-fluoro-2′-hydroxy-6′-methyl-[1,1′-biphenyl]-4-yl)-1H-indazol-3-yl)propanoic acid;
3-(6-chloro-5-(4′-fluoro-2′-hydroxy-3′-methoxy-[1,1′-biphenyl]-4-yl)-1H-indazol-3-yl)propanoic acid;
3-(6-chloro-5-(4′-(dimethylcarbamoyl)-[1,1′-biphenyl]-4-yl)-1H-indazol-3-yl)propanoic acid;
4-(6-chloro-5-(2′-hydroxy-3′-methoxy-[1,1′-biphenyl]-4-yl)-1H-indazol-3-yl)butanoic acid;
3-(6-chloro-5-(4′-(methylcarbamoyl)-[1,1′-biphenyl]-4-yl)-1H-indazol-3-yl)propanoic acid;
6-((3-(6-chloro-5-(2′-hydroxy-[1,1′-biphenyl]-4-yl)-1H-indazol-3-yl)propanoyl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid; and
6-((4′-(3-(2-carboxyethyl)-6-chloro-1H-indazol-5-yl)-[1,1′-biphenyl]-2-yl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid,
or a pharmaceutically acceptable salt, a tautomer, or a pharmaceutically acceptable salt of the tautomer thereof.

### Claim 12 (depends on 1)

The composition of claim 1, wherein the composition comprises the compound of Formula (I), a pharmaceutically acceptable salt, a tautomer, or a pharmaceutically acceptable salt of the tautomer thereof, in an amount of from about 1 mg to about 500 mg.

### Claim 13 (depends on 1)

The composition of claim 1, wherein the composition is formulated for oral administration.

### Claim 14 (depends on 1)

The composition of claim 1, wherein the composition comprises the compound of Formula (I), a pharmaceutically acceptable salt, a tautomer, or a pharmaceutically acceptable salt of the tautomer thereof, in the form of a microsphere particle.

### Claim 15 (depends on 14)

The composition of claim 14, wherein an amount of the microsphere particle has an average particle size (D50) of from about 80 μm to about 400 μm.

### Claim 16 (depends on 14)

The composition of claim 14, wherein the microsphere particle is coated with a coating to form a microcapsule.

### Claim 17 (depends on 16)

The composition of claim 16, wherein the coating comprises methacrylic acid, ethyl acrylate, or methyl methacrylate.

### Claim 18 (depends on 16)

The composition of claim 16, wherein an amount of the microcapsule has an average particle size (D50) of from about 200 μm to about 300 μm.

### Claim 19 (depends on 1)

A method for treating a condition, comprising administering to a subject in need thereof a therapeutically effective amount of the composition of claim 1, wherein the condition is an inflammatory condition, an autoimmune condition, or a functional gastrointestinal disorder.

### Claim 20 (depends on 1)

A method of making a composition of claim 1, comprising:
a) admixing, blending, and milling the compound of Formula (I), a pharmaceutically acceptable salt, a tautomer, or a pharmaceutically acceptable salt of the tautomer thereof; the matrix component; and the release modifier to form a mixture;
b) subjecting the mixture to a melt-spray-congeal process to form microsphere particles.
